Nav: Home

Humira provides effective, non-steroid alternative for eye inflammation

September 07, 2016

DURHAM, N.C. -- Patients suffering from noninfectious uveitis, a group of diseases that causes eye inflammation, can get effective treatment from a corticosteroid alternative that has previously been approved for treatment of arthritis and Crohn's disease, according to a study led by a Duke Health researcher.

The Food & Drug Administration recently approved the additional use of adalimumab (sold as Humira) for patients with noninfectious uveitis. Corticosteroids have traditionally been the only FDA-approved treatment for these diseases, although some doctors had prescribed adalimumab off-label.

The FDA's approval is limited to treatment of the three types of noninfectious uveitis that pose the greatest threat of vision loss.

Glenn Jaffe, M.D., a professor in the Department of Ophthalmology at Duke University School of Medicine, said adalimumab works to treat uveitis by targeting a protein that is thought to promote inflammation. Jaffe led one of two clinical studies that formed the basis of the FDA's approval and was senior author of the study appearing Sept. 8 in the New England Journal of Medicine (NEJM).

"Patients may have many unwanted side effects when taking steroids long-term, as many uveitis patients do," Jaffe said. "The goal of these studies was to determine whether there was an alternative that could replace or minimize the use of steroids. The studies also looked at whether an alternative would be better tolerated or more effective, yet still safe."

The study consisted of 217 adults who had active, non-infectious intermediate or posterior uveitis, or panuveitis. Participants were randomly assigned to a group that received either adalimumab or a placebo at the start of the trial and every two weeks thereafter. All participants also initially received standard doses of the corticosteroid prednisone, and continued to receive it in diminishing doses over the course of 15 weeks.

Jaffe and colleagues then analyzed patients' time to treatment failure, or how soon they saw a recurrence or worsening of one or more of four signs of inflammation: new areas of inflammation in the back of the eye, reduced visual clarity, more inflammatory cells in the front of the eye, or more cloudiness of the gel that fills the eye. Jaffe said the study focused on time to treatment failure because delaying or preventing inflammation is the key to successful treatment.

"It is the active inflammation, caused by the body's immune system reacting against itself, that can potentially permanently decrease the patient's vision and cause unwanted symptoms, such as eye pain and floaters in the field of vision," he said. "The hope is that by delaying or eliminating recurrences, the symptoms will be minimized or eliminated."

The researchers found that median time to treatment failure was 24 weeks in the adalimumab group and 13 weeks in the placebo group. Patients in the adalimumab group were also significantly less likely to experience treatment failure during the duration of the study (80 weeks) and they were at lower risk of treatment failure due to each of the four signs.

Jaffe said the study's results are significant not only because they indicate adalimumab delays treatment failure, but also because the investigation considered several signs as causes for treatment failure.

"Using these multiple, possible endpoints was something unique to this study," Jaffe said. "Since each of these signs can be associated with different types of uveitis, the study's results broaden the applicability of treatment for patients."

The study authors note, however, that patients in the adalimumab group reported serious adverse effects, such as respiratory tract infections and allergic reactions, more frequently than those in the placebo group.
-end-
In addition to Jaffe, co-authors include Andrew D. Dick, Antoine P. Brézin, Quan Dong Nguyen, Jennifer E. Thorne, Philippe Kestelyn, Talin Barisani-Asenbauer, Pablo Franco, Arnd Heiligenhaus, David Scales, David S. Chu, Anne Camez, Nisha V. Kwatra, Alexandra P. Song, Martina Kron, Samir Tari, and Eric B. Suhler.

AbbVie, the pharmaceutical company that manufactures and markets adalimumab as Humira, sponsored the study. Dr. Jaffe served as a consultant for AbbVie, and other study authors also report financial relationships with the company. Further author disclosures are available in the study's manuscript.

Duke University Medical Center

Related Inflammation Articles:

TWEAKing inflammation
Superficially, psoriasis and atopic dermatitis may appear similar but their commonalities are only skin deep.
More than a 'gut feeling' on cause of age-associated inflammation
Bowdish and her colleagues raised mice in germ-free conditions and compared them to their conventionally raised counterparts.
Inflammation: It takes two to tango
Signal molecules called chemokines often work in tandem to recruit specific sets of immune cells to sites of tissue damage.
Inflammation awakens sleepers
The inflammatory response that is supposed to ward off pathogens that cause intestinal disease makes this even worse.
Inflammation in regeneration: A friend or foe?
Scientists at Tokyo Institute of Technology have discovered a novel mechanism linking inflammation and organ regeneration in fish, which can be conserved among vertebrates.
New RNAi treatment targets eye inflammation
Scientists have developed a new RNA interference (RNAi) therapeutic agent that safely blocked ocular inflammation in mice, potentially making it a new treatment for human uveitis and diabetic retinopathy.
Every meal triggers inflammation
When we eat, we do not just take in nutrients -- we also consume a significant quantity of bacteria.
Inflammation halts fat-burning
Scientists at the University of Bonn have shown in mice that excess pounds can simply be melted away by converting unwanted white fat cells into energy-consuming brown slimming cells.
New tool uses UV light to control inflammation
Cornell researchers have developed a chemical tool to control inflammation that is activated by ultraviolet (UV) light.
Myocardial inflammation elevated in RA patients
Two new studies measure the prevalence of myocardial inflammation in RA patients without known cardiovascular disease, assess how it is associated with high disease activity and show how disease-modifying therapy may decrease this type of inflammation, according to new research findings presented this week at the 2016 ACR/ARHP Annual Meeting in Washington.

Related Inflammation Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Anthropomorphic
Do animals grieve? Do they have language or consciousness? For a long time, scientists resisted the urge to look for human qualities in animals. This hour, TED speakers explore how that is changing. Guests include biological anthropologist Barbara King, dolphin researcher Denise Herzing, primatologist Frans de Waal, and ecologist Carl Safina.
Now Playing: Science for the People

#SB2 2019 Science Birthday Minisode: Mary Golda Ross
Our second annual Science Birthday is here, and this year we celebrate the wonderful Mary Golda Ross, born 9 August 1908. She died in 2008 at age 99, but left a lasting mark on the science of rocketry and space exploration as an early woman in engineering, and one of the first Native Americans in engineering. Join Rachelle and Bethany for this very special birthday minisode celebrating Mary and her achievements. Thanks to our Patreons who make this show possible! Read more about Mary G. Ross: Interview with Mary Ross on Lash Publications International, by Laurel Sheppard Meet Mary Golda...